Cardiology Highlight Reel 2015 – Diabetes and CVD

Details & Video

Diabetes and CVD

Learn about the first clinical trial in history to show a CV benefit of a glucose-lowering drug!

Join Dr. Darren McGuire in conversation discussing the latest clinical trials of glucose-lowering agents for cardiovascular safety and efficacy.

Video Time: 22 min (Chapter selection enabled)
Program Interactivity: 5 min
CME Credits: This program is eligible for MOC RCPSC, Section 2 credits or you are eligible to claim up to 5 Mainpro+ certified credits by completing the CFPC’s Linking Learning to practice exercise.
Target Audience: Family Physicians, Cardiologists, Internists, Endocrinologists, Nephrologists

 

Program Preview

Click image above to play the program preview.



To watch the full program,
please login or register

 

Program Overview

The Cardiology Highlight Reel 2015 series engages world-renowned experts in conversation about the most important advances in cardiovascular medicine in 2015. Presented in short interviews, this program is a must-see for all clinicians managing patients with, or at risk for, cardiovascular disease.

In this segment, Dr. Darren McGuire discusses the latest clinical trials of glucose-lowering agents for cardiovascular safety and efficacy.

Participate in this eCME program and stay informed!

Cardiology Highlight Reel program flyer

Diabetes and CVD program flyer

CME Credits

This program is eligible for MOC RCPSC, Section 2 credits or you are eligible to claim up to 5 Mainpro+ certified credits by completing the CFPC’s Linking Learning to practice exercise.

You will receive your Certificate of Completion following participation in the interactive program elements located under the “Certificate” tab in the program player window.  A link to the Linking Learning to Practice exercise on the CFPC website will be included in your certificate.

Faculty


Potential for conflicts of interest:

Some speakers in this program have received payment/funding from the organizations supporting this program.
Speaker disclosures will be declared within the presentations.

Dr.-Milan-Gupta Co-Chair
Milan Gupta, MD, FRCPC, FACC
Associate Clinical Professor, Dep’t of Medicine
McMaster University
Assistant Professor, Dep’t of Medicine
University of TorontoMedical Director
Canadian Cardiovascular Research Network
Brampton, ON
Dr.Narendra Singh Co-Chair
Narendra Singh, MD, FRCPC, FACC, FAHA
Director, Clinical Research
Atlanta Heart Specialists
Clinical Assistant Professor
Georgia Regents University
Atlanta, GA
Dr. Darren McGuire Guest Faculty
Darren McGuire, MD, MHSc
Professor of Medicine, University of Texas
Southwestern Medical Center
Dallas, TX

Agenda

 

Introduction 1 min
A paradigm shift 1 min
  • Establishing CV safety of diabetes drugs
  • Exploring potential CV benefit of diabetes drugs
1 min
Incretins

  • DPP-IV Inhibitors
  • GLP-1 receptor agonists
7 min
SGLT2 Inhibitors

  • Mechanism of action
  • CV Effects
3 min
Discussion 9 min

Sponsorship

CCRN sm

This program has been developed by the Canadian Cardiovascular Research Network, a not-for-profit academic research and CHE organization, and is supported through educational grants received from:

 

  • Amgen Canada
  • AstraZeneca Canada
  • Boehringer Ingelheim Canada
  • Sanofi Canada